Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: 2025 Eurostat Trade Data and Economic Impact
Recruiting Observational

The Role of Priors in Hallucinatory Perception in Parkinson's Disease

NCT07427498 · tracked via the Priya Life Science France tracker
Phase
Observational
Started
2026-04-28
Last updated
2026-09-30

Condition(s) studied

PARKINSON DISEASE (Disorder)

Study summary

The goal of this observational study is to better understand the mechanisms of hallucinations in patients with Parkinson's disease. The main question it aims to answer is:

Do prior expectations increase the rate of false perceptions during a visual stimulus detection task more in Parkinson's disease patients with visual hallucinations compared to those without?

Participants will undertake a computer task involving face detection and a battery of neuropsychological tests.

Eligibility

Sex
ALL
Min age
18 Years
Max age
85 Years
Healthy volunteers
Accepted
Inclusion Criteria: * Adults diagnosed with Parkinson's disease (with or without visual hallucinations) or healthy volunteers. * Age 18 - 85 years. * Consent to participate. Exclusion Criteria: * Currently participating in another clinical or therapeutic trial involving the testing of a drug treatment. * Inability to perform cognitive tests due to: Non-psychiatric (somatic) conditions likely to affect cognitive abilities. Peripheral sensory or motor deficits. Acute clinical conditions (e.g., agitation, impaired consciousness). * Diagnosis of dementia. * Individuals covered by Articles L1121-5 to L1121-8 of the French Public Health Code (Code de la Santé Publique), including: Pregnant women, women in labor, or breastfeeding mothers. Individuals deprived of liberty by judicial or administrative decision. Individuals receiving psychiatric care under Articles L. 3212-1 and L. 3213-1 (excluding those covered by Article L. 1121-8). Individuals admitted to a healthcare or social institution for purposes other than research. Minors or adults under legal guardianship or unable to express consent. \- Individuals with a hierarchical relationship to any professional involved in the study. Only for healthy volunteers: \- Personal history of diagnosed neurological disorders. Post-Inclusion Exclusion: \- Participants included in the study but found to have a MoCA score below 24 will be excluded from the study.

Primary outcome measure(s)

  • Effect of Prior Expectations on False Alarm Rates in Parkinson's Disease Patients With and Without Visual Hallucinations — Baseline
    The primary outcome measures the false alarm rate during a visual stimulus detection task, specifically the percentage of trials in which participants report perceiving a stimulus when none was presented. The study will assess whether prior expectations (cues indicating the likelihood of a stimulus) increase false alarm rates more in Parkinson's disease patients with visual hallucinations compared to those without. The primary statistical analysis will test for an interaction effect (p \< 0.05) between cue (prior expectation), stimulus presence, and group (patients with vs. without hallucinations) using a generalized linear mixed model.

Trial sites (2)

FacilityCityRegionStatus
CHU Grenoble Alpes Grenoble France Recruiting
Grenoble University Hospitals La Tronche France Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07427498 on ClinicalTrials.gov ↗ ← All trials in France